Inhibition of the Rise in FFA by Acipimox Partially Prevents GH-Induced Insulin Resistance in GH-Deficient Adults
Autor: | Esa Laurila, Mikael Segerlantz, Leif Groop, Per Manhem, Margareta Bramnert |
---|---|
Rok vydání: | 2001 |
Předmět: |
Adult
Blood Glucose Male medicine.medical_specialty Acipimox Endocrinology Diabetes and Metabolism medicine.medical_treatment Glucose uptake Clinical Biochemistry Fatty Acids Nonesterified Carbohydrate metabolism Biology Biochemistry Endocrinology Insulin resistance Double-Blind Method Lipid oxidation Internal medicine medicine Humans Insulin Pancreatic hormone Hypolipidemic Agents Biochemistry (medical) Middle Aged Lipid Metabolism medicine.disease Glucose Basal (medicine) Growth Hormone Pyrazines Female Insulin Resistance Energy Metabolism Oxidation-Reduction medicine.drug |
Zdroj: | The Journal of Clinical Endocrinology & Metabolism. 86:5813-5818 |
ISSN: | 1945-7197 0021-972X |
Popis: | To test the hypothesis that GH-induced insulin resistance is mediated by an increase in FFA levels we assessed insulin sensitivity after inhibiting the increase in FFA by a nicotine acid derivative, Acipimox, in nine GH-deficient adults receiving GH replacement therapy. The patients received in a double blind fashion either Acipimox (500 mg) or placebo before a 2-h euglycemic (plasma glucose, 5.5 +/- 0.2 mmol/liter) hyperinsulinemic (serum insulin, 28.7 +/- 6.3 mU/liter) clamp in combination with indirect calorimetry and infusion of [3-(3)H]glucose. Acipimox decreased fasting FFA by 88% (P = 0.012) and basal lipid oxidation by 39% (P = 0.015) compared with placebo. In addition, the insulin-stimulated lipid oxidation was 31% (P = 0.0077) lower during Acipimox than during placebo. Acipimox increased insulin-stimulated total glucose uptake by 36% (P = 0.021) compared with placebo, which mainly was due to a 47% (P = 0.015) increase in glucose oxidation. GH induced insulin resistance is partially prevented by inhibition of lipolysis by Acipimox. |
Databáze: | OpenAIRE |
Externí odkaz: |